Small-molecule irreversible tyrosine kinase inhibitors as high potent agents have led to improvements in disease-free and overall survival in patients with HER2-amplified cancer. The approved ...

Signal transducer and activator of transcription factors (STATs) are proteins that can translocate into the nucleus, bind DNA, and activate gene transcription. STAT proteins play a crucial role in ...

Within that partnership, SunRock agreed to develop ADCs for cancer using Debiopharm's linker technologies, including for tumors expressing HER2 and HER3. The firms signed a new partnership agreement ...

Breast cancer is one of the most common cancers globally,6 with HR+/HER2- being the most prevalent subtype, accounting for approximately 70% of cases.7,8,9 Over 40% of HR+/HER2- breast cancer cases ...

The de-escalation of therapy helps avoid unnecessary toxicity from treatment, making it an important consideration during the treatment of patients with brain cancer or metastases, Dr. Manmeet Singh ...

HER2-positive metastatic breast cancer was once considered a “death sentence,” Dent said at a press conference, but now patients can survive on therapy for years, which presents its own ...

Ipatasertib plus with fulvestrant (Faslodex) led to significantly longer progression-free survival (PFS) compared with placebo and fulvestrant in patients with estrogen receptor (ER)-positive, ...

SAN DIEGO, CA, USA I June 03, 2025 I Avenzo Therapeutics, Inc. (“Avenzo”), a clinical-stage biotechnology company developing next-generation oncology therapies, today announced initiation of a Phase 1 ...

Background: Neoadjuvant taxane, carboplatin and trastuzumab plus pertuzumab is associated with excellent treatment outcomes. The neoCARHP study aimed to evaluate the efficacy and safety of a ...

Background: Vepdegestrant, an oral PROTAC (PROteolysis TArgeting Chimera) ER degrader, showed encouraging clinical activity and was well tolerated in a phase 1/2 study in pretreated patients (pts) ...